Vedanta Biosciences

Therapies that modulate pathways of interaction between the human microbiome and the host immune system

Also Clin2 hepatic encephalopathy; VE416 Clin2 food allergy; VE202 Clin1 IBD; VE800 Clin1 solid tumors; VE707 Clin0 bacterial infections

Vedanta Biosciences is developing a class of drugs to modulate the human microbiome. The human microbiome contains trillions of microbes that are important for preserving our health and stimulating immune responses. Dysfunction of the microbiota has been linked with several diseases; however, it is now hoped that the microbiota offers a new target class for therapeutics. Vedanta has one of the largest, most diverse culture collections of gut bacteria in the world and is using their discovery platform to identify defined bacterial consortia with drug-like properties that can be used to create oral therapies. Currently, Vedanta’s pipeline includes product candidates for C.difficile infection, inflammatory bowel disease, Gram-negative infections, solid tumors and food allergies.